At the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Disease, Cerevance presented new clinical findings for its investigational Parkinson’s disease (PD) treatment, solengepras.

At 90 days, participants randomized to the Felix NeuroAI transcutaneous peripheral nerve stimulation (TPNS) system showed ...

Our Killer50 companies traditionally enjoy a strong start to a new year. In 2024, nine companies (six in the Life Sciences segment) raised a collective $711m. The big winners then were quantum ...

Merck is paying $25 million upfront to tap into Cerevance's NETSseq transcriptomics technology, used to discover proteins that are either over- or under-expressed in disease states, and is also ...

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease (PD) and anti-tau therapies, which are ...